文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Clinical characteristics of elderly patients with proton pump inhibitor-refractory non-erosive reflux disease from the G-PRIDE study who responded to rikkunshito.

作者信息

Sakata Yasuhisa, Tominaga Kazunari, Kato Mototsugu, Takeda Hiroshi, Shimoyama Yasuyuki, Takeuchi Toshihisa, Iwakiri Ryuichi, Furuta Kenji, Sakurai Kouichi, Odaka Takeo, Kusunoki Hiroaki, Nagahara Akihito, Iwakiri Katsuhiko, Furuta Takahisa, Murakami Kazunari, Miwa Hiroto, Kinoshita Yoshikazu, Haruma Ken, Takahashi Shin'ichi, Watanabe Sumio, Higuchi Kazuhide, Fujimoto Kazuma, Kusano Motoyasu, Arakawa Tetsuo

机构信息

Department of Internal Medicine and Gastroenterology, Saga Medical School, 5-1-1 Nabeshima, Saga 849-8501, Japan.

出版信息

BMC Gastroenterol. 2014 Jul 2;14:116. doi: 10.1186/1471-230X-14-116.


DOI:10.1186/1471-230X-14-116
PMID:24990161
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4090183/
Abstract

BACKGROUND: The incidence and severity of gastroesophageal reflux disease (GERD) in Japan tends to increase in elderly women. Rikkunshito (RKT), a traditional Japanese medicine, acts as a prokinetic agent and improves gastric emptying and gastric accommodation. Our previous prospective randomized placebo-controlled study showed that RKT combined with a standard-dose of rabeprazole (RPZ) significantly improved the acid-related dysmotility symptoms (ARD) in elderly patients with proton pump inhibitor (PPI)-refractory non-erosive reflux disease (NERD). This study aimed to evaluate clinical characteristics of elderly PPI-refractory NERD patients with ARD symptoms who responded to RKT. METHODS: Two hundred forty-two patients with PPI-refractory NERD were randomly assigned to 8 weeks of either RPZ (10 mg/q.d.) + RKT (7.5 g/t.i.d.) (RKT group) or RPZ + placebo (PL group). Among them, 95 were elderly (≥65 years) with ARD (RKT group: n = 52; PL group: n = 43). We analyzed the changes using the 12 subscale score of frequency scale for the symptoms of GERD (FSSG) and 15 items of the Gastrointestinal Symptom Rating Scale at 4 and 8 weeks and compared the therapeutic efficacy between the 2 groups. RESULTS: There were no marked differences in baseline demographic or clinical characteristics in the 2 groups except for rate of current smoking. The FSSG score (mean ± SD at 0, 4, and 8 weeks) in both the RKT (16.0 ± 7.0; 9.9 ± 8.4; 7.0 ± 6.4) and PL (15.1 ± 6.4; 10.9 ± 6.7, 11.1 ± 8.5) groups significantly decreased after treatment. However, the degree of improvement of total and ARD scores of FSSG after the 8-week treatment was significantly greater in the RKT group than in the PL group. Combination therapy with RKT for 8 weeks showed significant improvement in 3 subscale scores (abdominal bloating, heavy feeling in stomach and sick feeling after meals) of the ARD domain and 1 subscale score (heartburn after meals) of the reflux symptom domain. CONCLUSIONS: RKT may be useful for improving GERD symptoms in elderly PPI-refractory NERD patients with ARD. Thus, RKT was particularly effective for resolving postprandial GERD symptoms (heavy feeling in stomach, sick feeling, and heartburn after meals). TRIAL REGISTRATION: (UMIN000005880).

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dde9/4090183/50e5bede71f8/1471-230X-14-116-3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dde9/4090183/04610d33e16f/1471-230X-14-116-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dde9/4090183/4c41de6d8a3f/1471-230X-14-116-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dde9/4090183/50e5bede71f8/1471-230X-14-116-3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dde9/4090183/04610d33e16f/1471-230X-14-116-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dde9/4090183/4c41de6d8a3f/1471-230X-14-116-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dde9/4090183/50e5bede71f8/1471-230X-14-116-3.jpg

相似文献

[1]
Clinical characteristics of elderly patients with proton pump inhibitor-refractory non-erosive reflux disease from the G-PRIDE study who responded to rikkunshito.

BMC Gastroenterol. 2014-7-2

[2]
A randomized, placebo-controlled, double-blind clinical trial of rikkunshito for patients with non-erosive reflux disease refractory to proton-pump inhibitor: the G-PRIDE study.

J Gastroenterol. 2014-10

[3]
Rikkunshito improves symptoms in PPI-refractory GERD patients: a prospective, randomized, multicenter trial in Japan.

J Gastroenterol. 2011-11-15

[4]
Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs-TORNADO study: a multicenter prospective study by the Acid-Related Symptom Research Group in Japan.

J Gastroenterol. 2011-8-24

[5]
Efficacy and safety of hangeshashinto for treatment of GERD refractory to proton pump inhibitors : Usual dose proton pump inhibitors plus hangeshashinto versus double-dose proton pump inhibitors: randomized, multicenter open label exploratory study.

J Gastroenterol. 2019-4-29

[6]
Efficacy of the addition of prokinetics for proton pump inhibitor (PPI) resistant non-erosive reflux disease (NERD) patients: significance of frequency scale for the symptom of GERD (FSSG) on decision of treatment strategy.

Intern Med. 2010

[7]
Irsogladine maleate and rabeprazole in non-erosive reflux disease: A double-blind, placebo-controlled study.

World J Gastroenterol. 2015-4-28

[8]
Characteristics of refractory gastroesophageal reflux disease (GERD) symptoms -is switching proton pump inhibitors based on the patient's CYP2C19 genotype an effective management strategy?

Intern Med. 2015

[9]
Clinical efficacy of Yukgunja-tang combined with a proton pump inhibitor for refractory gastroesophageal reflux disease: study protocol for randomized, double-blind, double-dummy clinical trial.

BMC Complement Med Ther. 2023-12-7

[10]
Esophageal Motility and Rikkunshito Treatment for Proton Pump Inhibitor-Refractory Nonerosive Reflux Disease: A Prospective, Uncontrolled, Open-Label Pilot Study Trial.

Curr Ther Res Clin Exp. 2017-4-4

引用本文的文献

[1]
The positive role of Chinese herbal medicine as an adjunctive therapy for refractory gastroesophageal reflux disease: A systematic review and network meta-analysis.

Medicine (Baltimore). 2025-5-23

[2]
Clinical efficacy of Yukgunja-tang combined with a proton pump inhibitor for refractory gastroesophageal reflux disease: study protocol for randomized, double-blind, double-dummy clinical trial.

BMC Complement Med Ther. 2023-12-7

[3]
Kampo Medicine for Various Aging-Related Symptoms: A Review of Geriatric Syndrome.

Front Nutr. 2020-7-15

[4]
Different Traditional Herbal Medicines for the Treatment of Gastroesophageal Reflux Disease in Adults.

Front Pharmacol. 2020-7-16

[5]
Herbal Therapies in Functional Gastrointestinal Disorders: A Narrative Review and Clinical Implication.

Front Psychiatry. 2020-7-10

[6]
Efficacy and safety of hangeshashinto for treatment of GERD refractory to proton pump inhibitors : Usual dose proton pump inhibitors plus hangeshashinto versus double-dose proton pump inhibitors: randomized, multicenter open label exploratory study.

J Gastroenterol. 2019-4-29

[7]
Recent Advances in the Pharmacological Management of Gastroesophageal Reflux Disease.

Dig Dis Sci. 2017-12

[8]
Tailored therapy guided by multichannel intraluminal impedance pH monitoring for refractory non-erosive reflux disease.

Cell Death Dis. 2017-9-7

[9]
An analysis of 342 patients with refractory gastroesophageal reflux disease symptoms using questionnaires, high-resolution manometry, and impedance-pH monitoring.

Medicine (Baltimore). 2017-2

[10]
Pharmacokinetic Profiles of Active Ingredients and Its Metabolites Derived from Rikkunshito, a Ghrelin Enhancer, in Healthy Japanese Volunteers: A Cross-Over, Randomized Study.

PLoS One. 2015-7-17

本文引用的文献

[1]
A randomized, placebo-controlled, double-blind clinical trial of rikkunshito for patients with non-erosive reflux disease refractory to proton-pump inhibitor: the G-PRIDE study.

J Gastroenterol. 2014-10

[2]
Kampo medicines for gastrointestinal tract disorders: a review of basic science and clinical evidence and their future application.

J Gastroenterol. 2013-3-16

[3]
The herbal medicine rikkunshito exhibits strong and differential adsorption properties for bile salts.

Exp Ther Med. 2012-4

[4]
Potentiation of ghrelin signaling attenuates cancer anorexia-cachexia and prolongs survival.

Transl Psychiatry. 2011-7-26

[5]
Rikkunshito improves symptoms in PPI-refractory GERD patients: a prospective, randomized, multicenter trial in Japan.

J Gastroenterol. 2011-11-15

[6]
Comparisons of symptoms reported by elderly and non-elderly patients with GERD.

J Gastroenterol. 2011-10-8

[7]
Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs-TORNADO study: a multicenter prospective study by the Acid-Related Symptom Research Group in Japan.

J Gastroenterol. 2011-8-24

[8]
Effect of Rikkunshi-to on appetite loss found in elderly dementia patients: a preliminary study.

Psychogeriatrics. 2011-3

[9]
Epidemiology of FGID symptoms in Japanese general population with reference to life style.

J Gastroenterol Hepatol. 2011-4

[10]
Efficacy of Rikkunshito, a traditional Japanese medicine (Kampo), in treating functional dyspepsia.

Intern Med. 2010

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索